Tandem Diabetes Care Inc. (TNDM)

factsheet Factsheet
  • Market Capitalisation market-capitalisation-info $1,587 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-204 Mln

Tandem Diabetes Care Inc. (TNDM) Share Price

$22.49

As on 07-Dec-2023 09:40 EST

up-down-arrow $0.261.17%

  • Prev Close info

    $22.23

  • Day's Openinfo

    $22.12

  • Today's Highinfo

    $22.38

  • Today's Lowinfo

    $22.11

  • Today's Volumeinfo

    40,844

  • 52 Week rangeinfo

    $13.82 - 47.18

Please wait...

Tandem Diabetes Care Inc. (TNDM) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Tandem Diabetes Care (TNDM)
-49.97 46.90 -20.11 -45.17 -38.07 -8.53 -21.34
S&P BSE Sensex
14.27 7.02 5.53 11.01 15.54 14.51 12.72
#
-- -- -- -- -- -- --
As on 07-Dec-2023  |  #As on
2022
2021
2020
2019
2018
2017
2016
Tandem Diabetes Care (TNDM)
-70.14 57.32 60.51 56.99 1,484.72 -89.02 -81.80
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91 1.95

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Tandem Diabetes Care Inc. (TNDM) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Tandem Diabetes Care Inc. (TNDM)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Tandem Diabetes Care Inc. (TNDM)

        Pres, CEO & Director

        Mr. John F. Sheridan

        Exec. VP, CFO & Treasurer

        Ms. Leigh A. Vosseller

        Headquarters

        San Diego, CA

        FAQs for Tandem Diabetes Care Inc. (TNDM)

        The total asset value of Tandem Diabetes Care Inc. (TNDM) stood at $ 1,125 Mln as on 31-Mar-23

        The share price of Tandem Diabetes Care Inc. (TNDM) is $22.49 (NASDAQ) as of 07-Dec-2023 09:40 EST. Tandem Diabetes Care Inc. (TNDM) has given a return of -38.07% in the last 3 years.

        Tandem Diabetes Care Inc. (TNDM) has a market capitalisation of $ 1,587 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Tandem Diabetes Care Inc. (TNDM) is 6.25 times as on 02-Jun-2023, a 0.55% premium to its peers’ median range of 4.02 times.

        Since, TTM earnings of Tandem Diabetes Care Inc. (TNDM) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Tandem Diabetes Care Inc. (TNDM) and enter the required number of quantities and click on buy to purchase the shares of Tandem Diabetes Care Inc. (TNDM).

        Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

        The CEO & director of Mr. John F. Sheridan. is Tandem Diabetes Care Inc. (TNDM), and CFO & Sr. VP is Ms. Leigh A. Vosseller.

        The promoters of Tandem Diabetes Care Inc. (TNDM) have pledged 0% of the total equity as on Dec-22.

        Tandem Diabetes Care Inc. (TNDM) Ratios
        Return on equity(%)
        -82.78
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.84
        Dividend yield(%)
        0

        No, TTM profit after tax of Tandem Diabetes Care Inc. (TNDM) was $-204 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $1,587.11 Mln
        • Revenue (TTM)revenue-information $794.69 Mln
        • Earnings (TTM) earning-information $-203.75 Mln
        • Cash date-information $519.59 Mln
        • Total Debt info $420.40 Mln
        • Insider's Holding 0.54%
        • Liquidity liquidity High
        • 52 Week range week-range $13.82 - 47.18
        • Shares outstanding share-outstanding 64,621,800
        • 10 Years Aggregate:

          CFO: $-75.13 Mln

          EBITDA: $-394.77 Mln

          Net Profit: $-632.33 Mln

        About The Company

        • IPO Date 14-Nov-2013
        • Pres, CEO & Director Mr. John F. Sheridan
        • Exec. VP, CFO & Treasurer Ms. Leigh A. Vosseller
        • Listing key-listing NASDAQ: TNDM
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.tandemdiabetes.com
        • Business

          Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin...  delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon